Treatment with Metadoxine and its impact on early mortality in patients with severe alcoholic hepatitis
Journal Title: Annals of Hepatology - Year 2014, Vol 13, Issue 3
Abstract
Background & Aim. Despite treatment with glucocorticoids, mortality remains high in patients with severe alcoholic hepatitis. Oxidative stress and depletion of mitochondrial glutathione are implicated factors in liver injury. The aim of this study was to evaluate the impact of the addition of metadoxine, a drug which possesses a multifactorial mechanism of action, including antioxidant properties, to standard treatment with glucocorticoids in patients with severe alcoholic hepatitis. Material and methods. This randomized open label clinical trial was performed in Mexico’s General Hospital (Registry Key DIC/10/107/03/043). We randomized 70 patients with severe alcoholic hepatitis. The first group received prednisone (40 mg/day), and the second group received prednisone (40 mg/day) plus metadoxine tablets (500 mg three times daily). The duration of treatment in both groups was 30 days. Survival at 30 and 90 days, development of complications, adverse events and response to treatment (Lille model) were assessed. Results. In the group receiving metadoxine, significant improvements were observed, as follows: survival at 30 days (74.3 vs. 45.7%, P = 0.02); survival at 90 days (68.6 vs. 20.0%, P = 0.0001). There was less development or progression of encephalopathy (28.6 vs. 60.0%, P = 0.008) and hepatorenal syndrome (31.4 vs. 54.3%, P = 0.05), and the response to treatment (Lille model) was higher in the metadoxine group (0.38 vs. 0.63, P = 0.001; 95% CI 0.11 to 0.40). There were no differences between groups regarding the development or progression of variceal hemorrhage or infection. The incidence of adverse events, mainly gastrointestinal, was similar in both groups. Conclusions. Addition of metadoxine to glucocorticoid treatment improves the short-term survival of patients with severe alcoholic hepatitis and diminishes the development or progression ofencephalopathy and hepatorenal syndrome.
Authors and Affiliations
Fátima Higuera-de la Tijera, Alfredo I. Servín-Caamaño, Javier Cruz-Herrera, Aurora E. Serralde-Zúñiga, Juan M. Abdo-Francis, Gabriela Gutiérrez-Reyes, José L. Pérez-Hernández
Keywords
Related Articles
- EP ID EP78395
- DOI -
- Views 104
- Downloads 0
Effects of Japanese herbal medicine inchin-ko-to on endotoxin-induced cholestasis in the rat
Background/Objective. Inchin-ko-to (ICKT) is an herbal medicine used in Japan to treat jaundice and liver fibrosis.We investigated the effect of oral ICKT supplementation on endotoxin-induced cholestasis in the rat. Mate...
Blue-Print for Elimination of Hepatitis C Viral Infection: One Step Closer
-
Does the size of the needle influence the number of portal tracts obtained through percutaneous liver biopsy?
Aim. Liver biopsy (LB) is often essential for the diagnosis and staging of chronic viral hepatitis. The aim of our paper was to establish if the size of the biopsy needle influences the number of portal tracts obtained...
Atypical Abdominal Pain in a Patient With Liver Cirrhosis
The causes of abdominal pain in patients with liver cirrhosis and ascites are well-known but occasionally, atypical causes arise. We report the case of a patient with a ruptured, confined abdominal aortic aneurysm.
Dendritic cells in NASH: Friend or foe?